Currently out of the existing stock ratings of Leah Cann, 2708 are a BUY (98.76%), 34 are a HOLD (1.24%).

Leah Cann

Work Performance Price Targets & Ratings Chart

Analyst Leah Cann, currently employed at BROOKLINE, carries an average stock price target met ratio of 41.67% that have a potential upside of 23.14% achieved within 192 days. Previously, Leah Cann worked at OPPENHEIMER.

Leah Cann’s has documented 130 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on MRNA, Moderna at 22-Jun-2022.

Wall Street Analyst Leah Cann

Analyst best performing recommendations are on SYRS (SYROS PHARMACEUTICALS).
The best stock recommendation documented was for MRNA (MODERNA) at 11/25/2020. The price target of $164 was fulfilled within 13 days with a profit of $54.82 (50.21%) receiving and performance score of 38.62.

Average potential price target upside

of $44.49 (30.37%) on AMGN (AMGEN).
of $31.73 (31.06%) on MRNA (MODERNA).
of $9.7 (30.04%) on MRTX (MIRATI THER).

AMGN Amgen CELG Celgene CTIC CTi Biopharma Corp MEIP MEI Pharma MRNA Moderna SQZ Sqz Biotechnologies Co CCCC C4 Therapeutics CRBU Caribou Biosciences KURA Kura Oncology SYRS Syros Pharmaceuticals MRTX Mirati Ther NTLA Intellia Therapeutics VSTM Verastem XFOR X4 Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Geoff Meacham (CITI)